The bioprocessing market is set to pass $44.19 billion by 2030 from $17.66 billion in 2021, reflecting a compound annual growth rate (CAGR) of 11.0% from 2022 to 2030, according to Next Move Strategy Consulting.

The current landscape of the bioprocessing industry is marked by dynamic developments, driven by advancements in biotechnology and the increasing demand for biopharmaceuticals, according to the company report. The surge is attributed to the rising prevalence of chronic diseases, the growing adoption of personalized medicine, and the expanding applications of bioprocessing in various sectors.

As bioprocessing becomes increasingly integral to the production of therapeutic proteins, vaccines, and other bio-based products, it stands out as a key enabler of the biotechnology revolution. The market is evolving to meet the demands of a changing healthcare landscape, environmental sustainability goals, and the need for efficient and scalable biomanufacturing processes.

Key market drivers

Rising Demand for Biopharmaceuticals: Next Move Strategy Consulting cites the escalating global demand for biopharmaceuticals is a primary driver propelling the bioprocessing market. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and vaccines are gaining prominence in the treatment of various diseases. As a result, there is a growing need for advanced bioprocessing technologies to meet the production demands of these complex and high-value therapeutic molecules.

Advancements in Single-Use Technologies: The adoption of single-use bioprocessing technologies is revolutionizing the industry. Single-use systems offer flexibility, cost-effectiveness, and reduced risk of cross-contamination. The market is witnessing a paradigm shift towards the integration of disposable components in bioprocessing workflows, driving efficiency and scalability.

Increasing Focus on Personalized Medicine: The paradigm of healthcare is shifting towards personalized medicine, and bioprocessing is at the forefront of this transformation. As the industry moves toward producing patient-specific therapies, bioprocessing technologies are evolving to accommodate the complexities of personalized medicine, including cell and gene therapies.

Growing Biomanufacturing Outsourcing: The trend of outsourcing biomanufacturing processes is gaining traction. Biopharmaceutical companies are leveraging the expertise of contract development and manufacturing organizations (CDMOs) to streamline production, reduce costs, and accelerate time-to-market. This shift is reshaping the competitive landscape of the bioprocessing market.

Environmental Sustainability: With a growing emphasis on sustainability, the bioprocessing industry is embracing eco-friendly practices. Bioprocessing technologies are being developed to minimize environmental impact, reduce energy consumption, and optimize resource utilization. The integration of green bioprocessing solutions aligns with global efforts toward a more sustainable and eco-conscious future.

Previous articleNovartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration
Next articleAn RNA-Based Switch for Dialing Gene Therapy Up or Down